Menold Daniel 4
4 · CymaBay Therapeutics, Inc. · Filed Oct 18, 2023
Insider Transaction Report
Form 4
Menold Daniel
Vice President, Finance
Transactions
- Sale
Common Stock
2023-10-16$13.76/sh−0$0→ 0 total - Exercise/Conversion
Common Stock
2023-10-16$3.45/sh+17,500$60,375→ 17,500 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-10-16−17,500→ 17,500 totalExercise: $3.45Exp: 2027-05-02→ Common Stock (17,500 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $13.98, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on April 27, 2018, and the remaining shares vested in equal monthly installments over the next 36 months.